Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study
Open accessThe DOI matches its Crossref record.
Abstract
The objectives of this paper are to evaluate the efficacy and tolerability of topiramate, given at the dose of 100 mg/day, in the prophylactic treatment of migraine. The hypothesis that migraine is the result of a condition of neuronal hyperexcitability and the quest for drugs that are able to limit the number of crises justifies the attempt to utilise the new antiepileptic drugs in the prophylaxis of this pathology, which is so important due to its high prevalence and due to the high disability it causes. The study was randomised double-blind versus placebo, lasting 16 weeks, and was preceded by a run-in period of 4 weeks. One hundred and fifteen patients were randomly allocated to treatment with topiramate (TPM) or placebo: 35 patients completed the study in the TPM group and 37 patients in the placebo group. At the end of the double-blind phase of study, in the TPM group, we recorded a significant reduction in the frequency of migraine crises (from 5.26 at baseline to 2.60 in the last 4 weeks), a significant reduction in the quantity of symptomatic drugs taken as compared to the placebo control group (from 6.17±1.80 SD to 2.57±0.80) and a significant downward trend in the number of days of disability over the 16-week period of therapy. In the TPM group, side effects were transient and well tolerated. TPM has thus proven its efficacy and tolerability in the prophylaxis of migraine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012) · Neurology · doi:10.1212/wnl.0b013e3182535d20 · Cited by 897
EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892
Systematic Review of Migraine Prophylaxis Adherence and Persistence
Hepp, Z., Bloudek, L. M., & Varon, S. F. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.1.22 · Cited by 333
Differential Effectiveness of Placebo Treatments: A Systematic Review of Migraine Prophylaxis
Meissner, K., Fässler, M., Rücker, G., Kleijnen, J., Hróbjartsson, A., Schneider, A., Antes, G., & Linde, K. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.10391 · Cited by 301
Exercise as migraine prophylaxis: A randomized study using relaxation and topiramate as controls
Varkey, E., Cider, Å., Carlsson, J., & Linde, M. (2011) · Cephalalgia · doi:10.1177/0333102411419681 · Cited by 258
Metadata
- Authors
- Mei, D., Capuano, A., Vollono, C., Evangelista, M., Ferraro, D., Tonali, P., & Di Trapani, G.
- Venue
- Neurological Sciences
- Published
- 2004-12
- Volume
- 25
- Issue
- 5
- Pages
- 245-250
- ISSN
- 1590-1874 (ISSN-L)
- 1590-3478
- OpenAlex
- W2016030981
- Cited by
- 72
- References
- 0
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. https://app.cochat.ai/papers/10.1007/s10072-004-0350-0
- The paper
- Mei, D., Capuano, A., Vollono, C., Evangelista, M., Ferraro, D., Tonali, P., & Di Trapani, G. (2004). Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurological Sciences. https://doi.org/10.1007/s10072-004-0350-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.